Data plan CO in Pharma (FWO DMP)

Data plan CO in Pharma

ADMIN DETAILS

Project Name: Data plan CO in Pharma (FWO DMP) - Data plan CO in Pharma
Project Identifier: CO in Pharma
Grant Title: G0D1522N
Principal Investigator / Researcher: Jo Seldeslachts
Description:

Common ownership - where several firms are partially owned by the same investor - and its impact on product markets has recently drawn a lot attention from both academics and policy makers. Institutional investors, such as BlackRock and Vanguard, have rapidly increased in importance in recent years. Their growing diversified portfolios have led to a steep increase in common ownership, which in turn has raised concerns worldwide about the potential distortion this creates into firms' decision making. Dubbed “the major new antitrust challenge of our time,” common ownership is an important, new topic in competition economics. But –although rapidly growing– research on the topic is still in its infancy. This project aims to assess in detail in US pharmaceutical industries the impact of common ownership on market entry strategies, and to investigate the resulting welfare consequences. The aimed contribution of the project is to give new and detailed insights in large investors’ influence in product markets, how this exactly affects firms’ entry strategies, and the resulting market outcomes in an important and well-suited industry for the research questions at hand, i.e. pharma.

1. GENERAL INFORMATION

Name applicant
Jo Seldeslachts

FWO Project Number & Title
G0D1522N - CO in Pharma

Affiliation
KU Leuven

2. DATA DESCRIPTION

Will you generate/collect new data and/or make use of existing data?
Yes to both

Describe in detail the origin, type and format of the data (per dataset) and its (estimated) volume. This may be easiest in a table (see example) or as a data flow and per WP or objective of the

project. If you reuse existing data, specify the source of these data. Distinguish data types (the kind of content) from data formats (the technical format).

The project is data-driven and seeks to answer how investors steer pharma companies' strategic decisions. The project will manage databases, based mainly secondary sources: the Thomson Reuters (TR) Global Ownership Database, the FDA Orange Book website, the The Par. IV Report and IMS Health. The raw data format depends on the database. TR data can be downloaded in Excel, the FDA and Par IV data contain data in html format, whereas we don't know yet in which format IMS Health transfers data. The TR data will be further cleaned with ultimate ownership data from NIC, which is in .txt format. These quantitive data will be cleaned, organised and compiled together into one, using several programming tools (Python, Matlab, SQL, Stata). The analysis will be done in Matlab and Stata.

3. LEGAL AND ETHICAL ISSUES

Will you use personal data? If so, shortly describe the kind of personal data you will use. Add the reference to your file in KU Leuven's Register of Data Processing for Research and Public Service Purposes (PRET application). Be aware that registering the fact that you process personal data is a legal obligation.
No

Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, add the reference to the formal approval by the relevant ethical review committee(s)
No

Does your work possibly result in research data with potential for tech transfer and valorisation? Will IP restrictions be claimed for the data you created? If so, for what data and which restrictions will be asserted?
No

Do existing 3rd party agreements restrict dissemination or exploitation of the data you (re)use? If so, to what data do they relate and what restrictions are in place?
Yes, some of the data used are based on commercial databases that restrict the use to 3rd parties.

4. DOCUMENTATION AND METADATA

What documentation will be provided to enable reuse of the data collected/generated in this project?
The target journals ask for a detailed database plan + replication script. We will, therefore, prepare these for this project as well.

Will a metadata standard be used? If so, describe in detail which standard will be used. If no, state in detail which metadata will be created to make the data easy/easier to find and reuse.
See the answer to the above question.

5. DATA STORAGE AND BACKUP DURING THE FWO PROJECT

Where will the data be stored?
The data will be stored on the KU Leuven cloud (+ a backup on the department server).

How is backup of the data provided?
See above

Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available then explain how this will be taken care of.
Yes, there should be enough capacity available on the KU Leuven cloud

What are the expected costs for data storage and back up during the project? How will these costs be covered?
The capacity is provided for free to KU Leuven researchers.

Data security: how will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?
The capacity is protected by the usual KU Leuven passwords.

6. DATA PRESERVATION AFTER THE FWO PROJECT

Which data will be retained for the expected 5 year period after the end of the project? In case only a selection of the data can/will be preserved, clearly state the reasons for this (legal or contractual restrictions, physical preservation issues, ...).
All data will be retained as publishing takes often longer than 5 years in economics.

Where will the data be archived (= stored for the longer term)?
We still have to decide this.

What are the expected costs for data preservation during the retention period of 5 years? How will the costs be covered?
The capacity is provided for free to KU Leuven researchers.

7. DATA SHARING AND REUSE

Are there any factors restricting or preventing the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)?
Yes, most of it will be covered by legal restrictions.

Which data will be made available after the end of the project?
The meta-data and scripts to reproduce the data.

Where/how will the data be made available for reuse?
Mostly together with the journal publications.

When will the data be made available?
Mostly together with the journal publications.

Who will be able to access the data and under what conditions?
Parties who have commercial agreements with the same databases, will be able to have access.

What are the expected costs for data sharing? How will the costs be covered?
See above.

8. RESPONSIBILITIES

Who will be responsible for data documentation & metadata?
Dr. Melissa Newham and the PI (Jo Seldeslachts) will be responsible.

Who will be responsible for data storage & back up during the project?
Dr. Melissa Newham and the PI (Jo Seldeslachts) will be responsible.

Who will be responsible for ensuring data preservation and reuse ?
Dr. Melissa Newham and the PI (Jo Seldeslachts) will be responsible.

Who bears the end responsibility for updating & implementing this DMP?
The PI (Jo Seldeslachts).